摘要
背景与目的:TopoⅡ与替莫唑胺(temozolomide,TMZ)治疗胶质瘤后产生化疗耐药的关系依然未清楚,本文探讨拓扑异构酶Ⅱ(topoⅡ)与胶质瘤细胞替莫唑胺化疗耐药性的关系。方法:替莫唑胺诱导构建耐药细胞株U251/TR,CCK-8法检测该细胞株的耐药性,RT-PCR法检测topoⅡ在U251和U251/TR中的表达变化。采用siRNA技术沉默耐药细胞株中topoⅡ的表达后,检测其对化疗药物敏感性变化。结果:成功构建TMZ耐药细胞株U251/TR,该细胞系对替莫唑胺有耐药性,其topoⅡ的表达明显升高,沉默topoⅡ的表达后,耐药性成功逆转。结论:TopoⅡ与替莫唑胺化疗耐药性有关。
BACKGROUND OBJECTIVE: Gliomas employ multiple mechanisms to resist chemotherapy.In this study,we investigated the relationship of topoisomerase II(topo II) and temozolomide(TMZ) sensitivity in glioma.METHODS: TMZ resistant cell line was established and the expression of topo II was detected by RT-PCR.The drug resistance was detected by CCK-8 kit.Topo II was silenced in resistant cell line,then we detected the chemotherapy sensitivity.RESULTS: The resistant cell line was established and the cell line had resistance to TMZ.The expression of topo II increased in the resistant cell line compared to U251 cells,the resistance was abolished after silencing topo II in the resistant cells.CONCLUSON: The expression level of topo Ⅱwas associated with the TMZ sensitivity in glioma
出处
《中国神经肿瘤杂志》
2012年第1期6-9,共4页
Chinese Journal of Neuro-Oncology
基金
国家自然科学基金(No 30973072)